



Azilect[®] (rasagiline) – First-Time Generic

- On January 3, 2017, Alvogen launched an AB-rated generic version of Teva Neuroscience's [Azilect \(rasagiline\)](#) tablets for the treatment of Parkinson's disease.
 - Teva's launch plans for an authorized generic are pending.
 - [Apotex](#) and [Orchid Healthcare](#) have received FDA approval of AB-rated generic versions of Azilect on September 12, 2013 and March 15, 2016, respectively. Settlement agreements will allow for launch of these products in early 2017.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.